EP3614939A1 - Procédé et système d'ablation photothermique simultanée et de thérapie photodynamique interstitielle - Google Patents

Procédé et système d'ablation photothermique simultanée et de thérapie photodynamique interstitielle

Info

Publication number
EP3614939A1
EP3614939A1 EP18790729.0A EP18790729A EP3614939A1 EP 3614939 A1 EP3614939 A1 EP 3614939A1 EP 18790729 A EP18790729 A EP 18790729A EP 3614939 A1 EP3614939 A1 EP 3614939A1
Authority
EP
European Patent Office
Prior art keywords
tissue
light
temperature
fluence rate
pdt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18790729.0A
Other languages
German (de)
English (en)
Other versions
EP3614939A4 (fr
Inventor
Gal Shafirstein
David BELLNIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of EP3614939A1 publication Critical patent/EP3614939A1/fr
Publication of EP3614939A4 publication Critical patent/EP3614939A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01K—MEASURING TEMPERATURE; MEASURING QUANTITY OF HEAT; THERMALLY-SENSITIVE ELEMENTS NOT OTHERWISE PROVIDED FOR
    • G01K7/00—Measuring temperature based on the use of electric or magnetic elements directly sensitive to heat ; Power supply therefor, e.g. using thermoelectric elements
    • G01K7/36—Measuring temperature based on the use of electric or magnetic elements directly sensitive to heat ; Power supply therefor, e.g. using thermoelectric elements using magnetic elements, e.g. magnets, coils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A61B18/22—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00577—Ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00642—Sensing and controlling the application of energy with feedback, i.e. closed loop control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00666—Sensing and controlling the application of energy using a threshold value
    • A61B2018/00678—Sensing and controlling the application of energy using a threshold value upper
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00696—Controlled or regulated parameters
    • A61B2018/00702—Power or energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A61B2018/00791—Temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A61B2018/00791—Temperature
    • A61B2018/00797—Temperature measured by multiple temperature sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A61B2018/00791—Temperature
    • A61B2018/00809—Temperature measured thermochromatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A61B2018/00791—Temperature
    • A61B2018/00815—Temperature measured by a thermistor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N2005/0612—Apparatus for use inside the body using probes penetrating tissue; interstitial probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A61N2005/0627—Dose monitoring systems and methods
    • A61N2005/0628—Dose monitoring systems and methods including a radiation sensor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres

Definitions

  • the present disclosure relates to photodynamic therapy.
  • I-PDT with porfimer sodium offers promising outcomes for patients with refractory locally advanced cancer.
  • the use of I-PDT with porfimer sodium (Photofrin®) is approved for palliation in patients with esophageal cancer or lung cancer with airway obstruction, who are non-candidates for surgery or radiation therapy.
  • I-PDT with porfimer sodium has been used, in compassionate care settings, to treat patients with head and neck squamous cell carcinoma.
  • a principal clinical goal has been to shorten treatment times by administering the therapeutic light at high dose rates (i.e., 400 mW/cm) that are clinically approved by the FDA for I-PDT with porfimer sodium.
  • PDT has also been viewed as beneficial when considering the relatively minor nature of adverse effects. Additionally, it has been noted that PDT provides excellent cosmetic outcomes. To date, it has been believed that during I-PDT the changes in tissue temperature do not affect the response. Physicians and researchers assumed that PDT is associated with minimal heating. The clinically approved, and used, light dose rate (400 mW/cm) for PDT or I-PDT with porfimer sodium was chosen arbitrarily, about 25 years ago. There was no systemic study to evaluate potential tissue heating during I-PDT. Several retrospective clinical studies suggest that PDT and I-PDT will result in retention of functional anatomy and other benefits. While offering improved palliative outcomes for patients with such advanced diseases, there remains a need for further improvement.
  • the present disclosure provides a method for treating a tissue.
  • a photosensitizer is administered to the tissue.
  • One or more optical fibers are placed in the tissue. For example, a portion (such as, for example, an end portion) of the one or more optical fibers are inserted in the tissue.
  • the optical fibers may be spaced apart from one another such that a light dose may be applied to the tissue.
  • the method includes applying a treatment light to the tissue by way of the one or more optical fibers.
  • a temperature of the tissue is measured during application of the treatment light.
  • the fluence rate (mW/cm 2 ) of the treatment light is modified based on the temperature of the tissue.
  • the fluence rate may be modified to be lower if the temperature of the tissue is higher than a predetermined threshold.
  • the fluence rate is modified to maintain a tissue temperature between 50°C and 65°C.
  • the fluence rate is modified to maintain a tissue temperature of substantially 60°C.
  • the fluence rate is modified to maintain a tissue temperature between 60°C and 90°C.
  • one or more dosimetry fibers may be placed in the tissue and configured to measure light dose (J/cm 2 ).
  • the optical fiber(s) and/or the dosimetry fiber(s) may be disposed within one or more light-transmitting catheters (LTCs) placed in the tissue.
  • LTCs light-transmitting catheters
  • each optical fiber may be disposed in a corresponding LTC.
  • each of a plurality of LTCs may contain an optical fiber and a dosimetry fiber.
  • the present disclosure may be embodied as a system for treating a tissue.
  • the system includes a light source and an optical fiber operably coupled to the light source.
  • the optical fiber is configured to deliver a light dose of treatment light to the tissue.
  • a temperature sensor is configured to measure a temperature of the tissue.
  • the temperature sensor may be any suitable sensor such as, for example, a thermistor, a thermal imaging sensor, a fiber optic, a magnetic resonance thermometer (providing volumetric temperature data), or the like.
  • the temperature sensor is configured to measure temperature at a plurality of locations throughout the volume of the tissue.
  • the temperature sensor comprises a plurality of temperature sensitive catheters.
  • a controller such as, for example, a programmable microprocessor, is in communication with the temperature sensor and configured to modify a fluence rate of the treatment light based on a measured temperature.
  • the controller is configured to modify the fluence rate of the treatment light to maintain a tissue temperature between 50°C and 65°C.
  • the controller is configured to modify the fluence rate of the treatment light to maintain a tissue temperature of substantially 60°C.
  • the controller is configured to modify the fluence rate of the treatment light to maintain a tissue temperature between 60°C and 90°C.
  • the system may further include a dosimetry fiber for measuring the light dose.
  • a spectrometer may be operably coupled to the dosimetry fiber.
  • the system may further include an LTC, and the optical fiber and/or the dosimetry fiber may be disposed in the LTC.
  • a second optical fiber is operably coupled to the light source and configured to deliver a second light dose of treatment light to the tissue.
  • the controller may be configured to modify a fluence rate of the second light dose based on the measured temperature.
  • the fluence rate of the second light dose may be modified based on a temperature at a second location of the tissue.
  • Figure 1 depicts a system according to an embodiment of the present disclosure
  • Figure 2 is a chart showing a method according to another embodiment of the present
  • Figure 3 shows a mouse being fitted with two optical fibers, each disposed within
  • I-PDT interstitial photodynamic therapy
  • Figure 4 is a chart showing intratumoral heating results for a light dose of 150 mW/cm
  • Figure 5 is a chart showing intratumoral heating results for a light dose of 350 mW/cm, 100 J/cm with and without photosensitizer;
  • Figure 6 is a chart showing tumor size over time in populations of mice, where a control population was untreated, a second population was treated with a light dose of
  • Figure 7 is a chart showing tumor size over time in populations of mice, where a control population was untreated, a second population was treated with a light dose of
  • Figure 8 is a chart showing tumor size over time in populations of mice, where a control population was untreated, a second population was treated with a light dose of
  • the present disclosure may be embodied as a method 100 for treating a tissue, for example, treating a tumor, of an individual using interstitial photodynamic therapy (I-PDT) ⁇ see Figure 2).
  • the method 100 includes administering 103 a photosensitizer to the tissue.
  • the photosensitizer may be, for example, porfimer sodium
  • the photosensitizer may be administered 103 by, for example, intravenous injection.
  • One or more optical fibers are placed 106 into the tissue to be treated.
  • the optical fibers may be placed at locations in the tissue according to a predetermined treatment plan.
  • the optical fiber(s) are placed 106 into the tissue by way of light- transmitting catheter(s) (LTCs) where each optical fiber is disposed in a light-transmitting catheter.
  • LTCs light- transmitting catheter(s)
  • a treatment light is applied 109 to the tissue by way of the one or more optical fibers.
  • the treatment light has a fluence (measured in, for example, joules per square centimeter— J/cm 2 ) and a fluence rate (measured in, for example, milliwatts per square centimeter— mW7 cm 2 ).
  • the method 100 includes measuring 112 a temperature of the tissue during application of the treatment light (i.e., during "treatment"). Measurement 112 of the tissue may be performed using any technique appropriate. For example, volumetric measurement may be accomplished using magnetic-resonance thermometry (MR thermometry or MRT). In another example, temperature is measured using a temperature-sensitive catheter. In embodiments where LTCs are placed in the tissue, a temperature-sensitive catheter may optionally be disposed in an LTC. Other methods for measuring 112 a temperature of a tissue may be used.
  • the fluence rate of the treatment light may be modified 115 based on the temperature of the tissue.
  • the fluence rate of the treatment light within the tissue e.g., intratumoral fluence rate
  • the fluence rate of the treatment light may be increased if the tissue temperature is lower than a second
  • the fluence rate is modified to maintain a tissue temperature of between 50-65°C, inclusive. In another exemplary embodiment, the fluence rate is modified to maintain a tissue temperature of less than 60°C. In another exemplary embodiment, the fluence rate is modified to maintain a tissue temperature of substantially 60°C. By substantially, embodiments may maintain the temperature of the tissue within a desired tolerance, for example, ⁇ 5°C, ⁇ 1°C, ⁇ 0.5°C, ⁇ 0.2°C, or other tolerance levels between these exemplary values, for example, in 2°C increments.
  • the temperature may be maintained at greater than 60°C and less than 100°C (or in some embodiments, less than 90°C) in order to avoid tissue carbonization.
  • the present disclosure may be embodied as a system 10 for treating tissue 90 using I-PDT is provided.
  • the system 10 includes a light source 12.
  • the light source 12 may be a laser configured to emit light at a wavelength for activating a selected photosensitizer.
  • the emitted light may be 630 nm.
  • An optical fiber 20 is operably coupled to the light source 12.
  • the optical fiber 20 is configured to deliver a light dose to the tissue 90.
  • the optical fiber 20 may have a cylindrical diffuser, a fiber with a flat-cut end, or other configuration.
  • Embodiments of the system 10 may include additional optical fibers, for example, the embodiment depicted in Figure 1 includes a second optical fiber 20 for delivering a second light dose to the tissue 90.
  • the system 10 includes a temperature sensor 30 for measuring a temperature of the tissue 90.
  • the temperature sensor 30 may be configured to measure the temperature of the tissue 90 at more than one location, for example, more than one 3-D location within the tissue 90.
  • the temperature sensor is a magnetic-resonance thermometer.
  • the temperature sensor comprises one or more temperature- sensitive catheters (e.g., a thermistor disposed in a catheter).
  • the system 10 may include a light-transmitting catheter 22
  • the system 10 further includes a controller 40 in communication with the temperature sensor 30.
  • the controller 40 is configured to modify a fluence rate of the treatment light based on the temperature of the tissue 90, as described above.
  • the controller 40 is a programmable microprocessor, programmed to modify the treatment light based on a signal received from the temperature sensor.
  • the treatment light may be modified by adjusting the intensity of the light source, attenuating the light emitted from the light source, independently attenuating the light in each optical fiber, or any other technique for increasing or decreasing the fluence rate of the treatment light delivered to the tissue via the optical fiber(s).
  • Some embodiments of the presently-disclosed system may include a dosimetry fiber 25 for measuring a light dose.
  • the dosimetry fiber 25 may be disposed in an LTC 22, for example, within a lumen 23 of an LTC 22.
  • the dosimetry fiber 25 may be operably coupled to a spectrometer 27 for measuring the light dose delivered to the tissue. In this way, a desired total dose may be delivered while also maintaining the temperature of the tissue in a desired range for effective photothermal ablation (or other synergistic effect when combined with I-PDT).
  • the mechanism of action in photodynamic therapy involves the generation of reactive oxygen species and radicals through light activation of photosensitizer in the presence of oxygen— i.e., an effective photoreaction.
  • oxygen- conserving light fluence rate mW/cm 2
  • I-PDT multiple optical fibers with a cylindrical diffuser or optical fibers with flat cut end are inserted into the tumor.
  • the light dose rate mW/cm
  • the light fluence rate depends on the light dose rate delivered from the optical fibers.
  • Photofrin is the only approved photosensitizer in the treatment of obstructing esophageal, non-small cell endobronchial lung cancer and high-grade dysplasia in Barrett's esophagus.
  • the FDA-approved light dose rate for I-PDT with Photofrin is 400 mW/cm length of the optical fiber cylindrical diffuser, which translates to a fluence rate of up to
  • MRT magnetic resonance thermometry
  • mice bearing locally advanced SCCVII tumors were treated when the tumors reached a size of 9-10 mm in their largest diameter, and a volume of 400-500 mm 3 calculated from caliper measurements, as is known in the art.
  • the animals were randomly assigned to receive light only (no drug) or I-PDT by administering 5 mg/kg porfimer sodium 24 hours prior to light delivery. Mice were considered cured if there was no palpable tumor any time at or after 60 days post I-PDT.
  • I-PDT Interstitial Photodynamic Therapy
  • the laser light (treatment light) was delivered through one to three 0.98 mm diameter optical fibers with 20 mm cylindrical light diffuser RD20 (Medlight SA, Ecublens,
  • the cylindrical light diffusers were connected to 1.0 Watt laser diode modules that emit 630 ⁇ 3 nm light (ML6500, Modulight Inc., Tampere, Finland). During light delivery, a custom made template was utilized to guide the placement of the laser fibers into the tumor, as shown in Figure 3. Magnetic Resonance Thermometry
  • Magnetic resonance thermometry (MRT) by proton resonance frequency methods was carried out in a 4.7 Tesla preclinical scanner using the ParaVision 3.0.2 imaging platform (Bruker Biospin, Billerica MA) and a 35 mm quadrature transceiver coil.
  • Figures 4 and 5 show that there was a temperature increase during the interstitial light delivery, with and without drug. These temperatures were averaged over the entire tumor volume.
  • Figure 6 shows the percentage of mice with tumors less than 4000 mm 3 over a period of 60 days post treatment.
  • Figure 8 shows the beneficial results of an embodiment of the presently-disclosed techniques using concurrent I-PDT and thermal ablation. It can be seen that the use of light without photosensitizer results in a cure rate of 40%. Despite the previous consideration that a lack of significant temperature change of the tissue was a benefit of PDT, Figure 8 shows that concurrent photothermal ablation and I-PDT resulted in a cure rate of 70%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

La présente invention concerne un procédé et un système de traitement d'un tissu à l'aide d'une thérapie photodynamique (PDT). Un photosensibilisateur est administré au tissu et une ou plusieurs fibres optiques sont placées dans le tissu. Une lumière de traitement est appliquée au tissu au moyen de la ou des fibres optiques. Une température du tissu est mesurée pendant l'application de la lumière de traitement, et un débit de fluence de la lumière de traitement est modifié sur la base de la température du tissu. Par exemple, le débit de fluence peut être modifié pour être inférieur si la température du tissu est supérieure à un seuil prédéfini.
EP18790729.0A 2017-04-29 2018-04-30 Procédé et système d'ablation photothermique simultanée et de thérapie photodynamique interstitielle Pending EP3614939A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492171P 2017-04-29 2017-04-29
PCT/US2018/030314 WO2018201156A1 (fr) 2017-04-29 2018-04-30 Procédé et système d'ablation photothermique simultanée et de thérapie photodynamique interstitielle

Publications (2)

Publication Number Publication Date
EP3614939A1 true EP3614939A1 (fr) 2020-03-04
EP3614939A4 EP3614939A4 (fr) 2020-09-16

Family

ID=63919282

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18790729.0A Pending EP3614939A4 (fr) 2017-04-29 2018-04-30 Procédé et système d'ablation photothermique simultanée et de thérapie photodynamique interstitielle

Country Status (4)

Country Link
US (2) US20200046997A1 (fr)
EP (1) EP3614939A4 (fr)
CA (1) CA3058949A1 (fr)
WO (1) WO2018201156A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109481013B (zh) * 2018-12-19 2021-05-28 南京康友医疗科技有限公司 一种具有热场监控功能的微波消融装置
CN109758227B (zh) * 2019-01-23 2021-12-21 深圳安泰创新科技股份有限公司 肿瘤消融模拟方法、装置、电子设备以及可读存储介质
WO2021194877A1 (fr) * 2020-03-25 2021-09-30 Lumeda Inc. Optimiseur de caractéristiques d'applicateur optique
US11771916B2 (en) * 2020-08-18 2023-10-03 Simphotek, Inc. Interstitial photodynamic therapy
WO2022266665A1 (fr) * 2021-06-17 2022-12-22 Lumeda Inc. Applicateur optique configurable
WO2023198724A1 (fr) * 2022-04-11 2023-10-19 Spectracure Ab Système et procédé de thérapies thermique et photodynamique combinée de tumeurs malignes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292320A (en) * 1992-07-06 1994-03-08 Ceramoptec, Inc. Radial medical laser delivery device
US5483958A (en) * 1994-01-25 1996-01-16 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Fluorescent-tipped dosimeter probe
IL154101A0 (en) * 2003-01-23 2003-07-31 Univ Ramot Minimally invasive controlled surgical system with feedback
US20090018531A1 (en) * 2007-06-08 2009-01-15 Cynosure, Inc. Coaxial suction system for laser lipolysis
US9033962B2 (en) * 2010-09-16 2015-05-19 Case Western Reserve University Photodynamic therapy including light pretreatment
WO2014062219A1 (fr) * 2012-10-16 2014-04-24 Ams Research Corporation Ablation par laser à récupération d'énergie électromagnétique
EP2799111A1 (fr) 2013-04-30 2014-11-05 Clinical Laserthermia Systems AB Appareil et procédé de commande de thermothérapie laser immunostimulante
US11065063B2 (en) 2015-07-02 2021-07-20 Board Of Regents, The University Of Texas System Utilization of laser interstitial thermotherapy guided with real time thermal MRI
US9987089B2 (en) * 2015-07-13 2018-06-05 University of Central Oklahoma Device and a method for imaging-guided photothermal laser therapy for cancer treatment
US11040217B2 (en) 2015-07-23 2021-06-22 Health Research, Inc. System and method for delivering dose light to tissue

Also Published As

Publication number Publication date
WO2018201156A1 (fr) 2018-11-01
US20230173301A1 (en) 2023-06-08
US20200046997A1 (en) 2020-02-13
EP3614939A4 (fr) 2020-09-16
CA3058949A1 (fr) 2018-11-01

Similar Documents

Publication Publication Date Title
US20230173301A1 (en) Method and system for concurrent photothermal ablation and interstitial photodynamic therapy
Arami et al. Remotely controlled near-infrared-triggered photothermal treatment of brain tumours in freely behaving mice using gold nanostar s
Hudson et al. Penetration of laser light at 808 and 980 nm in bovine tissue samples
US10441808B2 (en) Methods and devices for activating brown adipose tissue with light
US20060111762A1 (en) Device and method for photodynamic therapy of the nasopharyngeal cavity
US20230097605A1 (en) Damaging cancerous cells utilizing radio frequency waves in heating with heating enhanced by infusion or injection of glucose
US20240123253A1 (en) Photodynamic therapy devices, systems and methods
US11040217B2 (en) System and method for delivering dose light to tissue
Marijnissen et al. Pilot study on light dosimetry for endobronchial photodynamic therapy
US20190038909A1 (en) A Therapeutic Method and Device Therefor
Feather et al. Light delivery to tumour tissue through implanted optical fibres during photodynamic therapy
LT6795B (lt) Lazerinės terapijos šviesolaidinis zondas
Cassim et al. Iron oxide nanoparticle hyperthermia and radiation cancer treatment
RU2617090C1 (ru) Способ фотодинамической терапии злокачественных опухолей
US20230045729A1 (en) Implantable light delivery device
AU2005305606B2 (en) Device and method for photodynamic therapy of the nasopharyngeal cavity
WO2008085214A2 (fr) Traitement de la dysplasie oesophagienne de haut grade par thérapie photodynamique
CA3183491A1 (fr) Systemes, methodes et dispositifs pour endommager les cellules cancereuses par l'application d'energie a l'entiere cellule cancereuse et la zone du corps immediatement autour des cellules cancereuses
Bown Scientists and clinicians create a bright future for photodynamic therapy (PDT)
Weersink et al. Optical delivery and monitoring of photodynamic therapy of prostate cancer
Betz et al. Interstitial PDT Cancer Treatment
Lytle et al. Improved efficacy of SnET2 mediated PDT with the simultaneous application of selective hyperthermia
Missert et al. Photodynamic Therapy (PDT)
Day et al. Photothermal Therapy of Glioma in a Mouse Model With Near-Infrared Excited Nanoshells

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200813

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 18/00 20060101AFI20200807BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20211006